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Abstract: Regulation of protein phosphorylation is a primary cellular signaling mechanism. Many cellular responses to 
internal and external events are mitigated by protein kinase signaling cascades. Dysfunction of protein kinase activity has 
been linked to a variety of human pathologies, in the areas of cancer, inflammation, metabolism, cell cycle, apoptosis, as 
well as cardiovascular, neurodegenerative and autoimmune diseases [1-3]. As such, there is an important need for protein 
kinase activity detection methodologies for researchers engaged in Drug Discovery. A number of different technologies 
have been employed for the measurement of protein kinase activity, including radioactive methods, luminescent methods, 
and fluorescent methods. More recently, Homogeneous Time Resolved Fluorescence technology (HTRF
®), based on the 
principle of time-resolved fluorescent resonance energy transfer (TR-FRET), has been developed and applied for the 
measurement of protein kinase activity in vitro. This technology note describes the development of an HTRF
® assay for 
detection of Syk enzyme activity in a format consistent with the requirements of High-Throughput Screening (HTS) cam-
paigns currently used in drug discovery.  
INTRODUCTION 
  Kinases are one of the most interesting target families in 
drug discovery [4]. Mis-regulation of protein kinase activity 
has been implicated in numerous conditions, including can-
cers, inflammatory, and metabolic diseases [5,6]. The protein 
kinase family of enzymes contains more than 500 members, 
and is comprised of two sub-families, protein tyrosine (TK) 
and protein serine-threonine (STK), which mediate a wide 
spectrum of actions [7]. 
  A number of detection methodologies have been applied 
to protein kinase activity measurement. Radioactive method-
ologies, such as those utilizing scintillant-containing bead or 
plate surfaces, are generally considered the gold-standard for 
referencing kinase activity statistics, such as Km, kcat, and 
lead compound statistics, such as IC50. However, non-
isotopic, homogeneous methods are increasing preferred for 
HTS settings [8]. Luminescent-based technologies, including 
Enzyme Fragment Complementation assays, ELISA sys-
tems, and Amplified Luminescent Proximity Homogeneous 
Assay technology exhibit certain limitations due to the de-
structive nature of the assay readout. In these technologies, 
detection is a one-time-only event, and it is not possible to 
repeat readings of assay plates. Fluorescent-based detection 
offers greater flexibility, since multiple readings of the same 
assay plate are possible. Prompt fluorescence technologies 
typically exhibit high levels of background signals, limiting 
the sensitivity of these methods. In addition, the use of a 
single fluorophore may increase the likelihood of compound 
interference.  
 The  HTRF
® technology is used by leading drug discov-
ery researchers to screen for tyrosine and serine/threonine 
kinase inhibitors which provides a simple and robust assay 
platform for compound screening. HTRF
® is a versatile TR-
FRET technology developed for detecting molecular interac-
tions between biomolecules, and has been successfully   
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applied to protein kinase activity bioassays with purified 
enzymes, as well as with cellular lysates and membrane 
preparations [9-11]. All HTRF
® kinase assays follow the 
same general format, which includes a phosphospecific anti-
body conjugated to Eu
3+ cryptate (donor fluorophore), and an 
anti-tag or affinity molecule conjugated to XL665 or d2 (ac-
ceptor fluorophore) which recognizes the substrate, irrespec-
tive of its phosphorylation state. The time-resolved charac-
teristic of HTRF
® technology allows for the removal of 
nearly all environmental and compound effects. The use of a 
FRET-based readout has an additional advantage of specific-
ity for the intended biological moiety under investigation. 
HTRF
® reagents are unaltered in the presence of divalent 
cations, such as Mg
2+ or Mn
2+, and tolerate virtually any 
concentration of EDTA or ATP. HTRF
® chemistry is also 
able to withstand high concentrations of DMSO and other 
standard laboratory solvents. These features offer researchers 
involved in protein kinase activity monitoring a robust, 
flexible platform with which to perform their studies. 
  Detection of phosphorylation events have been validated 
using HTRF
® on small peptides as well as large protein sub-
strates [12]. The use of specific, physiologic substrates is 
generally preferred; however, production and purification of 
these substrates can be challenging. For this reason, many 
researchers look to small peptide substrates to facilitate pro-
tein kinase activity screening. Universal substrates are also 
an attractive concept, given the dramatic reduction in lead 
time for assay development that can be achieved using this 
approach. 
  For tyrosine kinase assays, two universal substrates, 
poly-Glu:Tyr (pGT) and poly-Glu:Ala:Tyr (pGAT) are 
available in the HTRF assay format. These two large peptide 
substrates (MW range: 25kDa & 44kDa) are useful tools for 
measuring tyrosine kinase activity, and yet there has been 
some concern among enzymologists about the kinetics of 
such a phosphorylation event. To address these concerns, a 
new HTRF
® KinEASE
™ kit was developed. It uses a unique 
biotinylated peptide substrate containing a single tyrosine 
phosphorylation site, which when phosphorylated is recog-Development of a HTRF
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nized by a monoclonal anti-phospho-tyrosine antibody, la-
beled with Eu
3+ cryptate. The detection is completed by the 
addition of streptavidin-XL665. This combination of sub-
strate and detection reagents has been validated on 59 unique 
tyrosine kinases, including both cytosolic and receptor-like 
TK’s. The HTRF
® KinEASE
™ assay platform is compatible 
with any ATP concentration, is easily miniaturized and has 
been successfully used for protein kinase selectivity studies 
as well as high-throughput screening campaigns. 
  In this study, tyrosine kinase Syk was used to compare 
the different assay formats available in HTRF
® readout. 
Syk Enzyme Role in Physiology 
  Spleen tyrosine kinase (Syk) is a non-receptor tyrosine 
kinase which has been linked to a variety of human signaling 
cascades. It is required for the transduction of immunorecep-
tor signals following antigen presentation. Syk is involved in 
B-cell receptor signaling, IgE receptor signaling in mast 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A typical HTRF
® protein kinase assay setup. 
HTRF
® protein kinase assays are characterized by the use of specific anti-phosphoresidue antibodies, generic affinity tags on the substrate 
molecule of interest, and specific anti-tag reagents for substrate catching. 
Table 1. Materials. Major Materials used in the Assay are Listed in Table 1. 
Name (Source)  Description  Catalog Number  Note 
ATP 
(Sigma-Aldrich) 
 A7699  
Poly-GT-biotin 
(Cisbio) 
61GT0BLD 44KDa;  Sequence: 
(GT)(4:1) 
Poly-GAT-biotin 
(Cisbio) 
61GATBLB 25KDa,  Sequence: 
(GAT)(6:3:1) 
TK substrate-biotin 
(Cisbio) 
Tyrosine kinase substrate 
62TK0PEB 1.5KDa;* 
PT66-K 
(Cisbio) 
61Y20KLB  
PY20-K 
(Cisbio) 
61Y20KLB   
TK antibody 
(Cisbio) 
Europium conjugated antibody 
specific for phosphorylated 
tyrosine residue 
62TK0PEB   
Streptavidin-XL665 
(Cisbio) 
Detection reagent  610SAXLB   
Staurosporine 
(Sigma-Aldrich) 
ATP-competitive inhibitor  S4400   
384-lv plate 
(Greiner) 
Black polystyrene  784067   
RubyStar
® 
(BMG) 
Microplate reader  N/A   
Syk enzyme  Tyrosine kinase  N/A  73kDa; specific activity = 
96pmol/g x min 
*sequence provided by Cisbio to KinEASE TK users by Cisbio upon request. 
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cells, and has been demonstrated to be essential for lympho-
cyte development in knock-out studies [13]. Because of its 
role, Syk has become a drug target for potential therapies in 
allergy and autoimmunity disorders [14-17]. Besides its 
prominent role in the immune system, Syk has also been 
reported to assist in tumor suppression in breast cancer, 
where it has key functionality with regard to restricting cel-
lular motility through its interaction with the actin and tubu-
lin cytoskeleton [18, 19]. 
MATERIALS AND METHODS 
Buffers 
  Enzyme, substrates and ATP are prepared in the enzy-
matic buffer, which consists of 50 mM HEPES pH 7.0, 
0.02% NaN3, 0.01% BSA 0.1mM Na2VO3, 5 mM MgCl2, 5 
mM MgCl2 and 1mM DTT. Detection reagents are prepared 
in detection buffer containing 50 mM HEPES pH 7.0, 0.1% 
BSA, 0.8 M KF and 20 mM EDTA. 
Tyrosine Kinase Assays 
  There are two main steps in the kinase assay: kinase reac-
tion and detection of the phosphorylated product by HTRF 
reagents. The kinase reaction was started by addition of ATP 
to a mixture containing the enzyme and substrates. After 10 
minutes or 30 minutes incubation at room temperature, the 
enzyme reaction was stopped by EDTA-containing buffer, 
which also contained europium-conjugated anti-phos-
phoresidue antibody and streptavidin-XL665(SA-XL665) to 
allow for detection of the phosphorylated peptide product. 
Following 1 hour incubation at room temperature fluores-
cence was measured with excitation of 337 nm and dual 
emission of 665 and 620 nm on the RubyStar microplate 
reader (BMG Lab Technologies). Signal was expressed in 
terms of HTRF ratio (fluorescence intensity @ 665 
nm/fluorescence intensity @ 620nm x 10,000). 
  The detailed assay protocol for SyK kinase assay is 
summarized in Table 2. The assay can be run in any plate 
format (96-, 384-, 1536-, 3456-well) by resizing each rea-
gent volume proportionally. The experiments described here 
were performed in a final assay volume of 20 μl, with n=3 
replicates for each condition.  
  Details of experimental steps for Syk activity assay in 
384-lv plate format are listed in Table 2. 
RESULTS AND DISCUSSION 
  Detection of phosphorylation events have been validated 
using HTRF
® on small peptides as well as large protein sub-
strates [12]. The use of specific, physiologic substrates is 
generally preferred; however, production and purification of 
these substrates can be challenging. For this reason, many 
researchers look to small peptide substrates to facilitate pro-
tein kinase activity screening. Universal substrates are also 
an attractive concept, given the dramatic reduction in lead 
time for assay development that can be achieved using this 
approach. 
  For tyrosine kinase assays, two universal substrates, 
poly-Glu:Tyr (pGT) and poly-Glu:Ala:Tyr (pGAT) are 
available in the HTRF assay format. These two large peptide 
substrates (MW range: 25kDa & 44kDa) are useful tools for 
measuring tyrosine kinase activity, and yet there has been 
some concern among enzymologists about the kinetics of 
such a phosphorylation event. To address these concerns, a 
new HTRF
® KinEASE
™ kit was developed recently. It uses a 
unique biotinylated peptide substrate containing a single 
tyrosine phosphorylation site, which when phosphorylated is 
recognized by a monoclonal anti-phospho-tyrosine antibody, 
labeled with Eu
3+ cryptate. The detection is completed by the 
addition of streptavidin-XL665. This combination of sub-
strate and detection reagents has been validated on 59 unique 
tyrosine kinases, including both cytosolic and receptor-like 
TK’s. The HTRF
® KinEASE
™ assay platform is compatible 
with any ATP concentration, is easily miniaturized and has 
been successfully used for protein kinase selectivity studies 
as well as high-throughput screening campaigns. 
  The first step in the development of an HTRF
® kinase 
assay is to determine a rough working range of enzyme and 
substrate. This is normally accomplished by running a matrix 
of enzyme titration versus substrate titration, with high levels 
of ATP (~100μM). Titrations of Syk enzyme were run at 
Table 2.  HTRF
® Kinase Assay Protocol 
Step Parameter  Value  Description 
1 Compound  0.5  L  DMSO 50%, HTRF
® Enzymatic buffer 1x 
2 Enzyme  5.5  L  Dilution in HTRF
® Enzymatic buffer 1x 
3  Incubation   15min  Room temperature, covered with plate seal 
4 Substrate  2  L  Dilution in HTRF
® Enzymatic buffer 1x 
5 ATP  2  L  Dilution in HTRF
® Enzymatic buffer 1x 
6  Incubation  10 or 30min  Room temperature, covered with plate seal 
7 Reagent  10  L  Europium Anti-P-MAb, SA-XL665 in HTRF
® 
Detection buffer 
8  Incubation  60 min  Room temperature 
9 Detection  HTRF
® mode  Rubystar plate reader 
Note: All experiments in this study were performed and completed in two working days. Development of a HTRF
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various concentrations of poly-GT-biotin, poly-GAT-biotin, 
or TK substrate-biotin. ATP was held constant at 100M. 
The enzymatic reaction was allowed to proceed for either 10 
minutes or 30 minutes at room temperature. SA-XL665 was 
kept in constant molar proportion (1:8) to the biotinylated 
substrate in all cases. This constant proportion of strep-
tavidin to biotin is necessary to avoid masking signals at the 
top and bottom titration points.  
HTRF
® Syk Assay with Poly-(GT)-Biotin and Poly-
(GAT)-Biotin Substrates 
  First, we established kinase activity levels at various en-
zyme and substrate concentrations. ATP was held constant at 
100μM, to avoid limiting reaction progress due to ATP con-
sumption. Syk enzyme showed higher activity with poly-GT-
biotin than with poly-GAT-biotin (data not shown). With 
poly-GT-biotin, MAb PT66-K produced better signal detec-
tion than MAb PY20-K (data not shown). Reaction times of 
10 minutes produced less signal than reaction times of 30 
minutes in all cases, as expected (data not shown). Fig. (2) 
shows titration of poly-GT-biotin using various concentra-
tions of Syk enzyme, and detection with MAb PT66-K and 
SA-XL665.  
  The assay system showed a signal increase which was 
both Syk-dependant and poly-GT-biotin dependant, indicat-
ing signal obtained is reflective of substrate phosphorylation. 
Under these conditions, 6.8nM Syk and 0.1μM substrate 
showed the best compromise between signal:noise ratio and 
linearity of response. This data highlights that the limiting 
reagent in this reaction is Syk enzyme, as evidenced by the 
significant drop off in activity with decreasing enzyme con-
centration. 
HTRF
® Syk Assay with KinEASE TK Substrate-Biotin 
  The Syk enzyme activity was much more efficient with 
the KinEASE TK substrate. Fig. (3) shows a comparison of 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (2). Titration of poly-GT-biotin vs. Syk enzyme. 
Various concentrations of Syk enzyme were run using different concentrations of poly-GT-biotin substrate. The optimal condition (6.8nM 
Syk, 0.1M substrate) produced a signal to background ratio of 8.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (3). Titration of Syk enzyme at 1μM substrate. 
Various concentrations of Syk enzyme were run using different substrates at a concentration of 1μM. The TK substrate-biotin showed the 
greatest performance, with the optimal condition (1.36nM Syk, 1μM TK substrate-biotin) producing a signal to background ratio of 43.9. 
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all tested substrates at an enzymatic concentration of 1μM 
substrate. 
  Syk enzyme showed dramatically higher signal output 
with TK substrate-biotin than either poly-GT-biotin or poly-
GAT-biotin. There are several explanations for this result. 
First, the KinEASE TK substrate may be a more functional 
substrate for Syk than poly-GT- or poly-GAT-biotin. The 
KinEASE TK substrate was developed for its ability to elicit 
high levels of activity from a broad panel of tyrosine kinases. 
Second, the affinity of KinEASE TK MAb for its substrate 
may be higher than that of PY20 or PT66 for either poly-GT-
biotin or poly-GAT-biotin. Higher affinity interactions in-
crease the probability of higher signal generation, since it is 
more likely to find partners in a bound step during measure-
ment. Finally, the KinEASE TK substrate has a signal phos-
phorylation site, while the other substrates have 20 or more 
potential phosphorylation sites (determined by sequence and 
molecular weight). As the anti-phospho MAb is generally 
limiting for signal output, it is possible that some fraction of 
antibody may bind to phosphorylated tyrosines on poly-GT-
biotin or poly-GAT-biotin which, because of their orienta-
tion and distance, do not allow FRET signaling to occur. 
This would limit the maximum signal achievable by the sys-
tem. It is important to note, however, that while the signal 
output was greatly increased with the use of KinEASE TK 
substrate, significant signal output was achieved with all 
three substrates. 
  From this experiment, the optimal concentration would 
be 1.36nM Syk enzyme with the 1M KinEASE TK sub-
strate. This condition represents excellent signal:noise per-
formance, while maintaining good linearity of the reaction, 
as evidenced by the shape of the enzyme titration curve. 
  As the performance of KinEASE TK substrate with Syk 
was so dramatic at 1μM, we then attempted to see whether 
acceptable assay performance could be obtained at lower 
substrate concentrations. Fig. (4) shows the results of Syk 
titration at 0.1μM and 0.01M substrate. 
  From this experiment, the optimal concentration would 
be 1.36nM Syk enzyme with the 0.1M KinEASE TK sub-
strate. This condition represents excellent signal:noise per-
formance, while maintaining good linearity of the reaction, 
as evidenced by the shape of the enzyme titration curve. 
While maximum signal:noise ratio is lower in this experi-
ment than in the previous, there are multiple advantages to 
utilizing 10-fold less substrate. By using lower concentra-
tions of substrate during the reaction step, the threshold for 
non-ATP competitive inhibitor potency is similarly lowered. 
In other words, a broader spectrum of non-ATP competitive 
inhibitor potencies can be detected. Additionally, since the 
consumption of SA-XL665 is tied proportionally to the con-
sumption of substrate, reducing substrate concentrations dur-
ing the enzymatic step simultaneously reduces assay cost per 
well.  
  The optimal condition as determined from the three ex-
periments depends greatly on the specific needs of the re-
searcher. If non-ATP competitive inhibitors are not desired, 
high concentration of substrate can be used, and enzyme 
consumption can be reduced. This is also a good option if 
enzyme is scarce or difficult to produce. If enzyme is abun-
dant, or if non-ATP competitive inhibitors are strongly de-
sired, substrate concentration can be minimized while main-
taining acceptable signal to noise levels for screening cam-
paigns. 
Determination of Syk Enzyme Kinetics 
  Following enzyme and substrate range determination, 
optimization of two further parameters is generally required 
before embarking on compound screening. Km (apparent) 
determination for ATP and substrate gives the researcher an 
understanding of the relative potency required for inhibitors 
to demonstrate activity under selected assay conditions. In 
this study we performed a Km analysis for the KinEASE TK 
substrate, using non-limiting ATP (100M). Results are 
shown in Fig. (5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Titration of Syk enzyme at 0.1μM substrate. 
Various concentrations of Syk enzyme were run using different substrates at a concentration of 0.1μM or 0.01 μM. The TK substrate-biotin 
showed the greatest performance under either concentration, with the optimal condition (1.36nM Syk, 0.1μM TK substrate-biotin) producing 
a signal to background ratio of 21.5. 
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Fig. (5). Km determination for KinEASE TK substrate with Syk enzyme. 
Various concentrations of Syk enzyme were run using different concentrations of TK substrate-biotin. Michaelis-Menten analysis of results 
fluorescence yielded a Km apparent value of 0.1μM TK substrate-biotin. The signal to noise ratio at this concentration of substrate (3.4nM 
Syk) was 30.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (6). Staurosporine inhibition of Syk activity. 
Various concentrations of the ATP-competitive inhibitor Staurosporine were incubated with Syk enzyme, prior to initiation of the kinase reac-
tion. Analysis of the resulting fluorescence yielded an IC50 concentration of 9.9nM. This value is consistent with previous published results. 
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  The KinEASE TK substrate showed apparent Km values 
of approximately 0.1M with R-squared values >0.98 in all 
cases. Researchers in search of non-ATP competitive inhibi-
tors generally would screen using a substrate concentration 
at or below apparent Km. Researchers interested in only 
ATP-competitive inhibitors generally would screen using a 
substrate concentration several fold (5-fold or more) about 
apparent Km. 
IC50 of Known Inhibitors 
As validation of the Syk/KinEASE TK assay system, we ran 
a titration of staurosporine, a known ATP-competitive in-
hibitor, using KinEASE TK substrate at 200nM, and ATP at 
10M. Results are shown in Fig. (6). 
  Staurosporine showed expected inhibition of Syk activ-
ity, with an IC50 value of 9.9nM, and an R-squared value 
above 0.97 for curve fit. This value is consistent with other 
reported values from the literature for staurosporine inhibi-
tion of Syk [20-22]. 
CONCLUSIONS  
  To further meet the needs of scientists involved in protein 
kinase research, the HTRF
® KinEASE
™ TK Kit has been 
developed as a unique and powerful tool for the screening of 
tyrosine kinases. With one biotinylated substrate, containing 
a single phosphorylation site, enzymatic activity can be 
measured for at least 59 unique tyrosine kinases with a single 
product. The performance of the unique TK substrate-biotin, 
as compared to other universal tyrosine kinase substrates, 
provides researchers vast flexibility in their assay design 
without sacrificing assay performance. Due to its single 
phosphorylation site, kinetic determinations such as Km ap-
parent are easily investigated.  
  Because of KinEASE
™ TK’s impressive signal to noise 
performance, enzyme and/or substrate concentrations can be 
minimized or maximized in order to suit the needs of each 
individual researcher. With enzymes at times being costly or 
difficult to produce, KinEASE
™ TK allows for a dramatic 
reduction in enzyme consumption while maintaining per-
formance requirements for screening. With its large dynamic 
range of functional substrate concentrations, and its applica-
bility to any ATP concentration, KinEASE
™ TK allows sci-
entists the opportunity to customize screening conditions to 
target the discovery of ATP-competitive inhibitors, ATP 
non-competitive inhibitors, or both. Additional information 
for HTRF
® kinase assays and other related reagents can be 
found on the web at www.HTRF.com. 
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